|
Update on type 2 diabetes mellitus drug treatment and drug usage-2020
|
|
| Author:
|
DR.W CLEMENT ATLEE, C L BAID METHA
|
| Abstract:
|
Type 2 diabetes brought about by Insulin resistance which bit by bit prompts to loss of beta cells activity. There will be no sufficient reaction from given portion of insulin. Expanded abdominal adipocyte triglyceride store in obese patient advance insulin resistance. Interferance of tissue insulin flagging course by the delivered fiery cytokines from adipocytes prompts to insulin resistance. Lessening in adiponectin (adipose specific) focus in type2 diabetes mellitus likewise causes insulin resistance. Hyperglycemia gets poisonous to beta cells. Because normal beta cells secrete more insulin in response to insulin resistance, insulin secretory deformity of beta cells created after a timeframe. In the event that diabetes is not dealt with appropriately, it can prompt renal, retinal, cardiovascular, neurological intricacies, wellbeing weakness, diabetic extreme lethargies and passing. Comprehension of own malady, diet control, work out, look at blood glucose level as often as possible and severe adherence to medicate treatment are more significant if there should be an occurrence of patient side consideration. On the off chance that diabetes is not constrained by diet and exercise, start monotherapy with oral hypoglycemic drug like metformin. On the off chance that patient is indicative, haemoglobin A1C (HbA1c) value esteem equvalent or more than 10 %, if patient tolerant not ready to accomplish target blood sugar level or target HbA1c after three months think about insulin therapy. While choosing pharmacological therapy consider the medications cardiovascular advantages, persistent age, other co dismal conditions, quiet inclinations, drug viability, safety and cost. Currently we are centering the older established drugs and the novel ant diabetic drugs which have scope in future in the treatment of type2 diabetes in different patient factors.
|
| Keyword:
|
Type 2 diabetes mellitus; Metformin; Incretin based therapy; Fixed dose combinations; Novel type 2 anti diabetic drug
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.SP1.355
|
| Download:
|
Request For Article
|
|
|